Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial | SpringerLink

Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial | SpringerLink: Purpose To determine the start exercise prescription dose in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving second-line hormone treatment and recommended phase II exercise...

Comments

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News